Harrow, Inc. (HROW)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$30.58+0.33%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- Forward P/E
- 10.8
- 52-week range
- $28.54 – $54.85
- 52-week change
- −27.70%
- EPS (trailing)
- −$0.99
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $272M (+36.42%)
- Net income
- −$5.1M
- Operating margin
- 11.2%
- Diluted EPS
- −$0.14
- Free cash flow
- $43.0M
From the company’s annual report on SEC EDGAR.
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the…
Headquarters: Nashville, United States · 373 employees · harrow.com